USTR launches Section 301 probe into German pharma pricing
On 19 June 2026, the U.S. Trade Representative initiated a Section 301 investigation into Germany's pharmaceutical pricing practices, alleging that the country's low reimbursement rates for innovative drugs force American patients to subsidize global R&D. The probe will determine whether Germany's pricing policies—including supplemental discounts and variable-rate rebates—are unreasonable, discriminatory, or burden U.S. commerce. Interested parties have until 10 August 2026 to submit comments; a public hearing is scheduled for 22 September 2026. This action follows months of bilateral talks and reflects the Trump administration's broader push for pharmaceutical producers to receive fair compensation globally.
Photo: SHVETS production / PexelsUSTR launches Section 301 investigation into German pharmaceutical pricing
On 19 June 2026, U.S. Trade Representative Jamieson Greer initiated a Section 301 investigation under the Trade Act of 1974 against Germany, alleging that the country's persistent underpayment for innovative pharmaceutical products is unreasonable, discriminatory, and burdens U.S. commerce.
Background and scope
The investigation follows a 12 May 2025 presidential directive instructing USTR to address foreign countries' practices that force American patients to pay a disproportionate share of global pharmaceutical R&D by suppressing drug prices below fair market value. Germany is the first target of this initiative, though the announcement references an April 2026 U.S.–UK pharmaceutical-pricing arrangement as a model for resolution.
According to USTR, German pricing mechanisms may include:
supplemental discounts in exchange for confidentiality of negotiated prices; and mandatory variable rate rebates.
USTR notes particular concern over Germany's reported plans to "fast-track legislation that would further reduce its spending on innovative pharmaceuticals," characterizing this as a "serious step backwards."
Procedural timeline and next steps
Under Section 302(b) of the Trade Act, USTR may self-initiate a Section 301 investigation. The investigation will examine whether Germany's acts, policies, or practices are unreasonable or discriminatory and burden or restrict U.S. commerce.
Key dates:
- 10 August 2026: Deadline for written comments and hearing requests
- 22 September 2026: Public hearing date
USTR has already requested formal consultations with Germany. Interested persons—including pharmaceutical manufacturers, exporters, and importers—may submit written comments and testimony summarizing their views on how German pricing policies affect their business. Details on comment and hearing-request procedures are available in the Federal Register notice and USTR's docket.
Who is affected
This investigation directly impacts:
- U.S. pharmaceutical manufacturers exporting to Germany (HS Chapter 30)
- Contract manufacturers and active-pharmaceutical-ingredient suppliers (HS Chapter 29)
- Importers and distributors of innovative drugs
- Companies with supply chains spanning both countries
Germany's response—or failure to negotiate a resolution—could trigger retaliatory tariffs or other Section 301 remedies within 12–18 months, depending on USTR's findings and negotiating progress.
What this means for shippers
Pharmaceutical exporters and importers must monitor this investigation closely. If Germany does not engage constructively in consultations or if USTR finds its pricing practices violate Section 301, tariffs on German pharmaceuticals or related chemical inputs could follow, materially increasing landed costs. File comments by 10 August 2026 if your business is affected; attend the 22 September hearing if you need to testify. Track USTR's findings and any retaliatory announcements—delays now compound supply-chain disruption later. Use /us-china-tariff-lookup to monitor emerging tariff schedules.
